FOX 04

Supports tissue rejuvenation, reduces age-related inflammation, and enhances overall vitality.

From AED 950.00

Format:

Do not freeze

Do not shake

GMP certified

Protect from sun

Refrigerate

Not sure about the right dosage?

Use our Peptide Dosage Calculator for optimal application

Main Information

FOX04-DRI is a synthetic senolytic peptide designed to selectively disrupt the interaction between FOXO4 and p53 in senescent cells. By promoting the safe clearance of dysfunctional “zombie” cells, it reduces chronic inflammation, supports tissue rejuvenation, and may contribute to healthier aging. FOX04-DRI is being investigated as a tool for longevity optimization, recovery enhancement, and regenerative medicine.

Scientific Background

Cellular senescence is one of the key processes behind aging. Over time, certain cells stop dividing but remain active, releasing harmful inflammatory signals often called the “zombie cell effect”. These so called senescent cells build up in tissues, slowing regeneration and contributing to age-related decline.FOX04-DRI is a specially designed peptide that helps the body clear these damaged cells. It works by breaking the link between two proteins (FOXO4 and p53) that normally keep senescent cells alive. Once this link is disrupted, only the harmful cells are removed — while healthy cells remain untouched.Early research has shown that FOX04-DRI may improve tissue health, reduce frailty, and support regeneration. Because of this, it is considered a next-generation anti-aging tool with promising applications in longevity and recovery.v

References

Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017;169(1):132–147.
Ogrodnik M, et al. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun. 2017;8:15691.
Zhu Y, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644–658.

Usage Instructions

You find the most important facts concerning usage below. For detailed guidance on preparation, administration, and dosage of your product, please refer to the product leaflet provided with your package or at the bottom of this page.

Administration route: Subcutaneous (preferred) or intramuscular
Needle size: 29–31G (subQ) or 25–27G (IM)
Preparation: Reconstitute lyophilized powder with bacteriostatic water before use
Storage: Store lyophilized vials at –20 °C; once reconstituted, refrigerate at 2–8 °C and protect from light
Timing: Typically administered in cycles, not continuously, due to senolytic mechanism

Dosage Information

Senolytic Protocol (Research Context)

5–10 mg, subcutaneous, once weekly or in intermittent cycles (e.g., 2–3 weeks on, followed by washout)
Short, pulsed dosing preferred to minimize off-target effects

Longevity / Recovery Research

5 mg weekly for 2–4 weeks, followed by evaluation phase

Often combined with NAD+ boosters or mitochondrial peptides for synergistic anti-aging effects

Important Warnings

For research use only — not approved for clinical therapy
Avoid continuous long-term use; FOX04-DRI is senolytic and designed for intermittent cycles
Not recommended during pregnancy, breastfeeding, or in individuals with active wounds/infections
Potential side effects (preclinical): fatigue, mild nausea, or transient tissue sensitivity
Always use sterile injection technique and rotate sites
Discontinue immediately if severe reactions or unexpected symptoms occur